In this video, Andrew A. Moshfeghi, MD, MBA, discusses results from a phase 1 study of an intravitreal hydrogel axitinib implant for wet AMD he recently presented at the virtual Angiogenesis, Exudation, and Degeneration meeting.
OTX-TKI from Ocular Therapeutix showed good safety, tolerability and efficacy.
Uncategorized